Mus vs Norway: Previously treated cases tested for RR-/MDR-TB (%)
Mus
100.0%
in 2022
Norway
100.0%
in 2024
Mus rank
1st
Norway rank
1st
Previously treated cases tested for RR-/MDR-TB (%) over time
- Mus
- Norway
How they compare
Mus currently reports 100.0% against 100.0% in Norway, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2005 it was Mus ahead.
Mus ranks 1st and Norway ranks 1st of 2 regions.
Mus has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Mus | Norway | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 92.0% | 60.0% | 32.0% | Mus |
| 2010s | 96.0% | 62.5% | 33.5% | Mus |
| 2020s | 100.0% | 82.3% | 17.7% | Mus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Mus or Norway?
- Mus, at 100.0% against 100.0% in Norway as of 2022.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Mus and Norway?
- 0.0%, with Mus ahead.
- How many years of comparable data are there for Mus and Norway?
- 18 years are reported by both, from 2005 to 2022.
- How do Mus and Norway rank globally for previously treated cases tested for rr-/mdr-tb?
- Mus ranks 1st and Norway ranks 1st of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.